Arctoris was featured in Drug Discovery World (DDW) in an article exploring how the integration of end-to-end laboratory automation and artificial intelligence is transforming drug discovery.
The piece highlights the limitations of traditional drug discovery approaches, which are often slow, costly, and reliant on manual experimentation. By contrast, combining automation with AI enables a more efficient and data-driven workflow, accelerating the identification and optimisation of drug candidates.
The article discusses how end-to-end automation platforms integrate robotic experimentation with data capture and analysis systems, allowing researchers to run complex experimental workflows with high precision and reproducibility. These systems can execute large numbers of assays while generating consistent, well-annotated datasets that support better decision-making.
Artificial intelligence plays a complementary role by analysing large datasets, identifying patterns, and guiding subsequent experimental design. Together, automation and AI enable faster iteration through the design–make–test–analyse (DMTA) cycle, significantly reducing the time required to progress from target identification to candidate selection.
In the article, Arctoris is highlighted as an example of a company applying this integrated approach through its Ulysses® automated drug discovery platform, which combines robotics, machine learning, and scientific expertise to generate high-quality experimental data at scale.